Davis Jerel Net Worth

The estimated Net Worth of Davis Jerel is at least $19.1 Million dollars as of 9 December 2022. Davis Jerel owns over 250,000 units of Repare Therapeutics stock worth over $5,885,407 and over the last 4 years Davis sold RPTX stock worth over $13,187,500.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Davis Jerel RPTX stock SEC Form 4 insiders trading

Davis has made over 3 trades of the Repare Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Davis sold 250,000 units of RPTX stock worth $4,000,000 on 9 December 2022.

The largest trade Davis's ever made was selling 750,000 units of Repare Therapeutics stock on 3 June 2022 worth over $9,187,500. On average, Davis trades about 96,154 units every 69 days since 2020. As of 9 December 2022 Davis still owns at least 2,094,451 units of Repare Therapeutics stock.

You can see the complete history of Davis Jerel stock trades at the bottom of the page.

What's Davis Jerel's mailing address?

Davis's mailing address filed with the SEC is C/O REPARE THERAPEUTICS INC., 7210 FREDERICK-BANTING, SUITE 100, ST-LAURENT, A8, .

Insiders trading at Repare Therapeutics

Over the last 4 years, insiders at Repare Therapeutics have traded over $111,956,457 worth of Repare Therapeutics stock and bought 8,747,790 units worth $117,182,784 . The most active insiders traders include Partners L P/Ilbiotechnolog..., David P Bonita, and Group, Llc Green Jeremy Red.... On average, Repare Therapeutics executives and independent directors trade stock every 15 days with the average trade being worth of $446,135. The most recent stock trade was executed by Lloyd Mitchell Segal on 28 March 2024, trading 5,141 units of RPTX stock currently worth $23,751.

What does Repare Therapeutics do?

Repare Therapeutics Inc., a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small-molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, a proprietary drug discovery program for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

Complete history of Davis Jerel stock trades at Repare Therapeutics

Repare Therapeutics executives and stock owners

Repare Therapeutics executives and other stock owners filed with the SEC include:

• Lloyd Mitchell Segal,
  Pres, CEO & Director
• Dr. Maria Koehler M.D., Ph.D.,
  Exec. VP & Chief Medical Officer
• Dr. Michael Zinda Ph.D.,
  Exec. VP & Chief Scientific Officer
• Dr. Laurence F. Akiyoshi Ed.D.,
  Exec. Vice-Pres of Organizational & Leadership Devel.
• Cameron Black,
  Exec. VP of Discovery
• Dr. Kim A. Seth,
  Exec. VP and Head of Bus. & Corp. Devel.
• Steve Forte,
  Exec. VP & CFO
• Dr. Agnel Sfeir Ph.D.,
  Co-Founder
• Dr. Frank Sicheri Ph.D.,
  Co-Founder
• Dr. Daniel Durocher Ph.D.,
  Co-Founder
• Steve Forte,
  EVP, CHIEF FINANCIAL OFFICER
• Maria Koehler,
  EVP, CHIEF MEDICAL OFFICER
• Ann D Rhoads,
  
• Steven H Stein,
  
• Samarth Kulkarni,
  
• Bio Ventures 2014, L.P.Mpm ...,
  
• Todd Foley,
  Director
• Ansbert Gadicke,
  10% owner
• Group, Llc Green Jeremy Red...,
  
• Advisors Llc Orbi Med Capit...,
  
• David P Bonita,
  
• Briggs Morrison,
  
• Carol Schafer,
  
• Ventures V, Llc Versant Oph...,
  
• Vantage I, L.P.Versant Vant...,
  
• Partners L P/Ilbiotechnolog...,
  
• Thomas Civik,
  
• Davis Jerel,
  Director
• Lloyd Mitchell Segal,
  PRESIDENT AND CEO
• Michael Zinda,
  EVP, CHIEF SCIENTIFIC OFFICER
• Susan Molineaux,